SEC Form 4 · accession 0001615219-17-000034
Decoy Therapeutics Inc. · DCOY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
William K. McVicar
Officer — President, R&D
Period of report
May 26, 2017
Accepted (ET)
May 30, 2017 · 12:55 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001615219
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $3.37 | May 26, 2017 | A | 200,000 | A | — | May 26, 2027 | Common Stock | 200,000 | 200,000 | D |
Explanation of responses
- F125% of the total shares underlying this option vest on April 5, 2018 and the remaining shares vest 1/48 per month over the next 36 months thereafter, subject to continued service to the Issuer through each vesting date.